Researchers discover the cellular reactions that trigger tumours
us scientists investigating the carcinogenic effects of tobacco smoke have, for the first time, uncovered the intricate cascade of reactions it triggers, leading to cell proliferation -- the genesis of tumours. Based on this knowledge, a research team from Cornell University and the National Cancer Institute in Bethesda, Maryland tested a drug that interrupts the chain of reactions and reported it might prevent cancers of the aerodigestive tract (from the mouth till the stomach).
The study findings, published in a recent issue of the Journal of Cancer Research (Vol 65, No 2), indicate serious consequences for passive smokers, too. "Passive smokers are also at risk because the smoke sets off similar reactions in their bodies. Nicotine per se doesn't cause cancer, it is the poly cyclic aromatic hydrocarbons in the smoke (produced when a cigarette is lit) that is carcinogenic and stimulates other carcinogenic reactions," comments P K Julka, professor, department of radiology and oncology, All India Institute of Medical Sciences, Delhi.
Other cell constituents clamour to be part of the (self-injurious) action. cox-2 picks out a type of fatty acid called arachidonic acid and converts it into prostaglandin, also a fatty acid. A certain level of prostaglandins is already present in the cell and is essential for normal cellular processes. But smoking increases the levels of prostaglandins which then start producing more of amphiregulin and transforming growth factor- a, and the cycle of reactions starts anew.
The role of prostaglandin is crucial. It induces proliferation (increase in the number of cells), followed by angiogenesis (as the cell begins to proliferate, the blood vessels and capillaries will also grow in number to provide nutrition to the growing tissue) and finally lead to anti-apoptosis (arrest of cell death). When the natural process of cell death is stopped but the new cells keep on being formed, tumour formation occurs and this eventually leads to cancer.
After discovering the series of reactions, the scientists tested a cancer drug -- ag 1478 -- and found it inhibited the production of both cox -2 and egfr tyrosine kinase. But it is too early to say whether it would be safe to use. Although, "there are other drugs like celecoxib that inhibit cox -2, and drugs such as gefitinib and tarceva (potential inhibitors of egfr tyrosine kinase) are still under trial, more research is required to know about their side effects as we are still evolving the process of carcinogenesis," adds Julka. The study provides a mechanism-based rationale to evaluate whether a selective inhibitor of cox -2 or egfr tyrosine kinase used alone or in combination can prevent the onset of tobacco-related cancer.
We are a voice to you; you have been a support to us. Together we build journalism that is independent, credible and fearless. You can further help us by making a donation. This will mean a lot for our ability to bring you news, perspectives and analysis from the ground so that we can make change together.
Comments are moderated and will be published only after the site moderator’s approval. Please use a genuine email ID and provide your name. Selected comments may also be used in the ‘Letters’ section of the Down To Earth print edition.